
Aug 14, 2026 · 54 min
GLP-1 drugs could rewrite the economics of eating
Best of Big Technology: How Ozempic Changes Our Bodies, Minds, and Economy — With Johann Hari
The medications promise major health benefits while raising unresolved questions about access, dependence, mental health, children, and industries built on consumption.
- 1GLP-1 drugs suppress appetite, but their effects may extend from individual eating behavior to the wider economy.
- 2High prices and unequal access could make the benefits of weight-loss medications available mainly to people who can afford them.
- 3Stopping treatment, changing emotional coping mechanisms, and prescribing to children expose risks that remain difficult to measure.
Don't miss
Hari argues that suppressing comfort eating may reveal emotional needs or redirect compulsions toward alcohol and other harmful behaviors.
The brief
Johann Hari joins Alex Kantrowitz to examine how GLP-1 drugs such as Ozempic alter appetite, eating behavior, and the economics of food consumption.
The conversation links compulsive eating to highly processed food and competing capitalist incentives, without reducing the food and pharmaceutical industries to a single conspiracy.
Hari explains how a longer-lasting version of the body’s GLP-1 signal can suppress hunger, then considers the shockwaves for food companies, airlines, and other businesses.
The benefits are constrained by high prices, unequal access, patent rules, and the possibility that patients regain weight or face harm when treatment becomes unaffordable.
The hardest questions arrive around emotional eating, addiction substitution, mental-health uncertainty, and whether children should receive powerful appetite-altering drugs.
Hari’s central warning is that changing appetite may expose needs that food once managed, making GLP-1 treatment a social and psychological intervention as well as a medical one.
What was said on this episode
48 statements · 19 positive · 26 negative · 1 mixed · 2 neutral
GLP-1 agonists are profoundly affecting bodies and the economy.
“GLP-1 agonists like Ozempic are having a profound impact on our bodies and economy.”
Listen at 0:00
U.S. obesity doubled, followed by another doubling of severe obesity.
“Between the year I was born and the year I turned 21, obesity doubled in the United States. And then in the next 20 years, severe obesity doubled again.”
Listen at 4:25
Obesity rises sharply where diets shift toward processed foods.
“Obesity explodes everywhere that makes one change.”
Listen at 4:53
Processed food undermines people’s ability to feel full.
“processed and ultra-processed food. undermines our ability to ever feel full”
Listen at 5:36
Modern food environments expose people to fullness-disrupting foods.
“we are all living in a version of Cheesecake Park now.”
Listen at 8:43
Processed food is a key cause of obesity and GLP-1 drug demand.
“it's the key reason why we have this huge obesity crisis and why there is such enormous demand for these new weight loss drugs.”
Listen at 8:59
Food companies continually optimize products to increase consumption.
“they are constantly figuring out ways to maximize the amount we eat.”
Listen at 10:10
Society should regulate food companies to prevent health harms.
“The democracy needs to do what it's meant to do and regulate them to prevent them from harming our children and screwing up our bodies and harming our health.”
Listen at 10:42
GLP-1 drugs extend the body’s satiety signal from minutes to about a week.
“What these drugs do... is they inject you with an artificial copy of GLP-1 that instead of sticking around for a few minutes, sticks around in your system for a whole week”
Listen at 15:13
GLP-1 drugs substantially increase users’ sense of satiety.
“these drugs do is they hugely boost your sense of satiety”
Listen at 16:26
GLP-1 drugs constitute a profound scientific breakthrough.
“this is a profound scientific breakthrough.”
Listen at 16:36
Artificial gut hormones substantially reduce food intake.
“If you inject people with artificial copies of those gut hormones, you massively reduce the amount they eat.”
Listen at 16:54
Ozempic reduced Hari’s intake and produced 42 pounds of first-year weight loss.
“It's why I went from eating 3,200 calories a day to about 1,800. It's why I lost 42 pounds in the first year.”
Listen at 17:01
Ozempic and Wegovy users lose 15% of body weight on average annually.
“the average person who takes Ozempic and Wagovi, they're the same thing with different labels, loses 15% of their body weight in a year.”
Listen at 17:12
Mounjaro users lose 21% of body weight on average annually.
“the average person who takes that loses 21% of their body weight in a year.”
Listen at 17:30
Average Triple G users lose 24% of body weight.
“the average person loses 24% of their body weight”
Listen at 17:39
GLP-1 drugs will have major effects on health, behavior, appearance, and the economy.
“this is a staggering breakthrough, which... will have staggering effects on human health, how we move, how we look, on the economy.”
Listen at 17:52
Obesity substantially increases cancer risk.
“obesity massively increases the risk of cancer.”
Listen at 18:50
Obesity causes or worsens more than 200 diseases and complications.
“obesity increases over 200 known diseases and complications, either causes or increases.”
Listen at 19:06
More than half the population will take GLP-1 drugs once cheap daily pills arrive.
“my prediction is that more than half of the population will be taking them when it's a daily pill that's a dollar a day.”
Listen at 22:57
GLP-1 drugs reduce heart disease, heart attack, or stroke risk by 20%.
“Reduces your risk of heart disease, heart attack or stroke by 20%”
Listen at 24:15
GLP-1 drugs may be lethal for people with eating disorders.
“for people with eating disorders, I really fear it will be lethal.”
Listen at 24:34
GLP-1 drugs could cause an opioid-like death toll among girls using them to starve.
“I think we've got an opioid-like death toll of young girls who use these drugs to starve themselves.”
Listen at 24:39
Regulators should urgently tighten regulation of GLP-1 drugs.
“it's one of the reasons we need to tighten the regulation around these drugs urgently.”
Listen at 24:44
Regulators should urgently tighten GLP-1 drug regulation.
“we need to tighten the regulation around these drugs urgently.”
Listen at 24:45
Big Pharma uses extensive lobbying to distort U.S. drug regulation.
“In the United States, Big Pharma employs armies of lobbyists to rig drug regulation in the United States”
Listen at 27:57
Drugs cost substantially more in the United States than Canada or Mexico.
“All drugs are radically more expensive in the United States than they are in Canada or Mexico”
Listen at 28:11
Not everyone who is overweight or obese should take GLP-1 drugs.
“I don't believe everyone who's overweight or obese should be taking these drugs.”
Listen at 28:42
Expanding GLP-1 production increases demand through visible weight-loss effects.
“the more they race, the more people want it”
Listen at 31:08
Compounded GLP-1 drugs carry inherent risks.
“There's an inherent risk in compounded versions for obvious reasons.”
Listen at 31:28
Patients removed from GLP-1 drugs will almost certainly regain weight.
“if you're thrown off, you'll almost certainly regain the weight.”
Listen at 32:52
Stopping GLP-1 drugs probably slows metabolism, but evidence remains uncertain.
“We don't know if taking these drugs and then coming off them slows down your metabolism. Probably does.”
Listen at 33:32
Stopping GLP-1 drugs could leave users heavier than without treatment.
“Could you actually end up fatter than you were if you hadn't taken the drug? We don't know, but it's a concern.”
Listen at 33:44
Weight gain raises the body’s biological weight set point.
“you do have an innate set point, but as you gain weight, your set point rises.”
Listen at 35:47
Diet and exercise fail to produce sustained weight loss for about 85% of people.
“diet and exercise, does not produce sustained weight loss for about 85% of people who try it.”
Listen at 35:55
GLP-1 drugs may lower the brain’s biological weight set point.
“One theory about what it may be doing to the brain is it may be lowering your biological set point.”
Listen at 38:49
GLP-1 drugs may dampen the brain’s reward systems.
“One theory about how these drugs work is they may be dampening your reward systems.”
Listen at 43:34
Many GLP-1 users report reduced pleasure in eating.
“There does seem to be some evidence that there's lots of people report losing their pleasure in eating after taking these drugs.”
Listen at 43:49
The broader reward-system effects of GLP-1 drugs remain unknown.
“We don't know, is the honest answer.”
Listen at 44:21
Bariatric surgery has an operative mortality rate of one in one thousand.
“One in a thousand people die in the operation”
Listen at 47:45
Bariatric surgery reduces seven-year heart-attack mortality risk by 56%.
“if you have bariatric surgery in the seven years that follow, you are 56% less likely to die of a heart attack.”
Listen at 47:58
Bariatric surgery is associated with nearly quadrupled suicide risk.
“after bariatric surgery, your suicide risk almost quadruples.”
Listen at 48:24
Obesity at age 18 implies a 70% lifetime diabetes risk.
“If you're obese when you're 18 years old, you have a 70% chance of developing diabetes in your life”
Listen at 50:23
Type 2 diabetes reduces average lifespan by 15 years.
“diabetes, type 2 diabetes, knocks 15 years off your life on average.”
Listen at 50:29
The long-term effects of GLP-1 drugs remain unknown.
“We don't know the long-term effects of these drugs.”
Listen at 50:47
Japan has no statistically significant childhood obesity.
“Japan where there is no childhood obesity.”
Listen at 51:22
Japan eliminated childhood obesity through concerted government policy.
“Japan was not a healthy country. A hundred years ago, I had one of the worst diets in the world. Right. This was done by absolutely concerted government policy.”
Listen at 51:42
Concerted government policy can eliminate childhood obesity.
“This was done by absolutely concerted government policy. We can do that, too. Obviously, we need to do that.”
Listen at 51:47
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Books & mentions
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.
